Stocksigma LogoStocksigma Logo

Laurus Labs Delivers Strong 1QFY27 Operating Performance Driven by CDMO Expansion

Laurus Labs reported strong 1QFY27 revenue of ₹2,026 Cr (up 29% YoY, 12% QoQ), led by robust CDMO growth

Laurus Labs Delivers Strong 1QFY27 Operating Performance Driven by CDMO Expansion

Laurus Labs Ltd · Investor Presentation · 18 Sept 2026, 11:51 pm

Laurus Labs Delivers Strong 1QFY27 Operating Performance Driven by CDMO Expansion Laurus Labs reported strong 1QFY27 revenue of ₹2,026 Cr (up 29% YoY, 12% QoQ), led by robust CDMO growth. EBITDA rose 66% YoY to ₹644 Cr with margins expanding 700 bps YoY to 31.8%, driven by an improved mix and operating leverage. Net profit surged 126% YoY to ₹368 Cr. The company is executing a >₹3,000 Cr capex plan across FY27-FY28, allocating >85% toward growth in CDMO, fermentation, peptides, and advanced biologics. Management guides for sustained >30% EBITDA margins from FY27 onward.

Original exchange filing (PDF)

More announcements from Laurus Labs Ltd

All Laurus Labs Ltd announcements